凉血口服液治疗急性弥漫性血管内凝血的临床研究

Clinical Research on Acute Difuse Intravascular Coagulation Treated with Cooling-Blood Oral Liquid

本文观察180例流行性出血热(EHF)并发弥漫性血管内凝血(DIC)患者,其中治疗组105例,对照组75例。在对原发病相同治疗的基础上,治疗组用凉血口服液纠正凝血异常,对照组用肝素抗凝或6氨基己酸抑制纤溶亢进 治疗组总有效率92.4％,对照组80％(p<0.05);平均止血天数,尿量和血尿素氮复常的平均天数及血小板和凝血酶时间复常的平均天数均较对照组缩短(以上各项p<0.01)。本研究表明,凉血口服液对急性DIC有较好的疗效,尤适于临床DIC消耗性低凝期和纤溶亢进期的治疗,而无肝素加重出血的弊端,亦无需凝血象监测。

The authors observed 180 cases of epidemic hemorrhagic fever (EHF) complicated by difuse intravascular coagulation (DIC), in which the treatment group (TG) was 105 cases and the control group (CG) 75 cases. On the basis of applying the same treatment to primary disease, the abnor- mal blood coagulation was rectified by Cooling-Blood oral liquid in TG while in CG the coagulation was opposed by heparin or the hyperfibroilysis was inhibited by 6-aminocaproic acid. The total effective rate was 92.4% in TG and 80% in CG (p<0. 05). In TG, the average days of hemostasis, recovery of urine volume, blood urea nitrogen, blood platelet and thrombase were all shortened comparying with these in CG (p<0. 01). This research shows that the Cooling-Blood oral liquid has a comparative good effect for acute DIC, especially being suitable to the stages of consumptive hypocoagulation and hyperfibroilysis.